There has been much recent discussion and debate surrounding cannabis in Canada, including the prescribing of medical cannabis for therapeutic purposes. Certain commentators – including the Canadian Medical Association (CMA) – have denounced the prescribing of cannabis for medical purposes due to a perceived lack of evidence related to the drug’s efficacy, harms, and mechanism of action. In this commentary, we present arguments in favour of prescribing medical cannabis in Canada.
The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study
: Cancer-related cachexia and anorexia syndrome (CACS) is a common phenomenon in cancer patients. Cannabis has been suggested to stimulate appetite but research on this issue has yielded mixed results. The current study aimed to evaluate the effect of dosage-controlled cannabis capsules on CACS in advanced cancer patients.Despite various limitations, this preliminary study demonstrated a weight increase of ≥10% in 3/17 (17.6%) patients with doses of 5mgx1 or 5mgx2 capsules daily, without significant side effects. The results justify a larger study with dosage-controlled cannabis capsules in CACS.
The boxing legend, 53, has landed a deal to help boost tourism in Antigua and Barbuda, where thousands of Brits visit every year.
More than 800 Americans have fallen ill and, as of Friday, at least 13 had died from a severe respiratory illness apparently linked to vaping. The mysterious illness left one Illinois teenager with lungs like those of a 70-year old.
Understanding Patients’ Process to Use Medical Marijuana: A Southern New Jersey Community Engagement Project
Given the necessity to better understand the process patients need to go through in order to seek treatment via medical marijuana, this study investigates this process to better understand this phenomenon. Specifically, Compassion Care Foundation (CCF) and Stockton University worked together to identify a solution to this problem. Specifically, 240 new patients at CCF were asked to complete a 1-page survey regarding various aspects associated with their experience prior to their use of medicinal marijuana-diagnosis, what prompted them to seek treatment, level of satisfaction with specific stages in the process, total length of time the process took, and patient’s level of pain.
Future Cannabis Strategies brings together business leaders from across the wider European Consumer-Facing Cannabis products category for 2 days of insight, discussion and debate into how cannabis product manufacturers can understand:
Tired of politicians dodging the debate on the legalization and normalization of cannabis in all its forms – from recreational and medical to the embrace of hemp as an alternative to manmade materials that harm the planet? Then perhaps it’s time for a Citizens’ Assembly…
The prescription of medical cannabis by a transitional pain service to wean a patient with complex pain from opioid use following liver transplantation: a case report
The purpose of this case report is to describe a patient with a preoperative complex pain syndrome who underwent liver transplantation and was able to reduce his opioid consumption significantly following the initiation of treatment with medical cannabis. Reductions in opioid consumption were achieved with the administration of medical cannabis in a patient with acute postoperative pain superimposed on a chronic pain syndrome and receiving high doses of opioids. Concurrent benefits of initiating medical cannabis may include improvements in pain profile and functional status along with reductions in opioid-related side effects. This highlights the potential for medical cannabis as an adjunct medication for weaning patients from opioid use.
A man grew cannabis plants to help his suffering wife with agonising pain from serious back and neck injuries.
She used the cannabis as part of a recipe for cakes that she could eat rather than smoking it and this was less addictive than painkillers, a court heard.
As a therapeutic agent, most people are familiar with the palliative effects of the primary psychoactive constituent of Cannabis sativa (CS), Δ(9)-tetrahydrocannabinol (THC), a molecule active at both the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor subtypes. Through the activation primarily of CB1 receptors in the central nervous system, THC can reduce nausea, emesis and pain in cancer patients undergoing chemotherapy.